4-Antibody AG Receives Additional Milestone Payments

Please login or
register
09.10.2012

4-Antibody AG today announced two additional milestone payments from the company’s existing collaboration with Human Genome Sciences (HGS) to discover and develop fully human therapeutic antibodies. Specific details of the payments, which were made prior to completion of HGS’ recent acquisition by GlaxoSmithKline plc, were not disclosed.

The collaboration with Human Genome Sciences (HGS) began in August 2011 and focused on applying 4-Antibody’s proprietary, high throughput, in vitro Retrocyte Display technology (Retroviral B lymphocyte Display) for the rapid discovery of fully human antibodies against novel HGS targets.  The Retrocyte Display technology is a potent tool for high quality therapeutic antibody discovery using a rapid flow cytometry approach.  Full-length immunoglobulin antibody libraries are expressed in mammalian B-lineage cells, the cell designed by nature for optimal antibody display, resulting in ‘better-behaved’, fully human antibodies.

Dr Robert Burns, 4-Antibody’s CEO, said: “The way in which the HGS collaboration progressed demonstrates 4-Antibody’s ability to use its technology platform to generate high quality leads direct from screening. Companies which are target rich, are key collaborators for us as they allow us to put the Retrocyte Display platform to work in multi-target projects.  At the same time, we will continue to seek out service deals around our technology which will provide access to our platform to the wider market through our recently established partnership with Evotec.”

4-Antibody is a biopharmaceutical company with a powerful fully-human antibody drug-discovery technology platform which is generating an emerging pipeline of antibody therapeutics.  The company, headquartered in Basel, was founded in 2002 and awarded the CTI Start-up Label in 2004.

0Comments

More news about

4-Antibody

Company profiles on startup.ch

4-Antibody

rss